Graft-versus-host disease (GVHD) represents a major complication after allogeneic hematopoietic stem cell transplantation [1] . Chronic GVHD (cGVHD) is a significant cause of morbidity, increased risk of infection, and reduced quality of life (QOL) after transplant, affecting 40% of patients. First-line systemic therapy consists of systemic corticosteroids, and response rates are variable. Second-and further-line options for treatment of steroidrefractory cGVHD are needed in 40-60% of cases, and most of the therapies available are less than ideal, with low response rates and significant toxicities [2] . The skin is the most commonly affected site (75%) [3, 4] . Cutaneous manifestations have a broad clinical spectrum, including lichen planus-like eruption, scleroderma, xerosis and ichthyosis, poikiloderma, dyspigmentation, acral erythema, keratosis pilaris-like and papulosquamous eruptions, and psoriasiform and eczematous eruptions [3, 4] . Although there are still no randomized studies demonstrating its efficacy, ruxolitinib, a JAK1/2 inhibitor, appears to be a promising therapy for GVHD, as reported in a few reports with a small number of patients [5] [6] [7] [8] . Its mechanism of action seems to be related to suppression of the proinflammatory signaling that mediates tissue damage and by the promotion of tolerogenic regulatory T (T-reg) cells [9] .
In this report, we share a real-life experience using ruxolitinib in the treatment of steroid-refractory cGVHD in 20 patients from a single center in Sao Paulo, Brazil.
We treated off-label 20 patients with steroid-refractory cGVHD from March 2016 to July 2017 with ruxolitinib. The starting dose was 5 or 10 mg twice daily, depending on the hematological parameters, and if the patient had good tolerance and no toxicities, the dose was increased until a maximum of 20 mg twice daily, at the physician's discretion. Patient and disease characteristics are shown in Table 1 . Organ sites affected and GVHD grading before starting ruxolitinib were classified according to the National Institutes of Health (NIH) 2014 criteria [10] . Steroidrefractory cGVHD was defined as any disease that failed to respond to previous immunosuppressive therapy with steroids at a dose of ≥0.5 mg/kg/day for at least 4 weeks or inability to taper it with or without additional immunosuppressive drugs. Treatment responses were evaluated at 1, 3, and 6 months after starting ruxolitinib and were categorized according to the NIH 2014 criteria [11] as a complete response (CR), partial response (PR), or lack of response (unchanged, mixed response, or progression). A CR to ruxolitinib was defined as a resolution of all disease manifestations in each organ or site involved. PR was defined as an improvement in at least one organ or site, without progression in any organ or site. Lack of response was defined as disease progression in any organ or site, outcomes that did not meet criteria for CR or PR, or in cases in which additional agents were used to control GVHD after treatment with ruxolitinib. Toxicities were defined according to National Cancer Institute Common Terminology Criteria for Adverse Events grades.
The 20 patients treated with ruxolitinib had moderate (11/20; 55%) or severe (9/20; 45%) NIH grade cGVHD before ruxolitinib was started. The median number of organ sites affected was 3 (range, 1-5), with 95% of patients presenting with skin involvement, 70% with mouth, 50% with eyes, 30% with gastrointestinal tract, 30% with pulmonary, 15% with liver, and 5% with joint and genital involvement. The median number of previous immunosuppressive treatments before starting ruxolitinib was 3 (range, 1-6).
The overall response rate was 75% (15/20): most of the patients who responded (73%) had achieved a PR. Four * Aliana Meneses Ferreira ali_ferreira@hotmail.com patients (27%) had a CR. Five patients had lack of response with ruxolitinib-four of them were considered as unchanged disease and one patient showed a mixed response. The median time to response was 3 (range, 1-14) weeks after initiation of ruxolitinib.
Among the 15 patients with responses to ruxolitinib, most had moderate cGVHD (10/15; 66%), and they were exposed to ruxolitinib relatively soon after the development of cGVHD (median of 16 months). The median number of previous therapies in this group of patients was 3. We noted a significant improvement particularly in skin, mouth, and eye involvement, with all responding patients reporting improvement in their general physical status and daily activities. Only 1 responding patient had cGVHD relapse 5 months after ruxolitinib was started. The relapse was successfully treated with short-term steroids, and ruxolitinib treatment was maintained. All responding patients are still on therapy, except for 2 in whom ruxolitinib treatment was ended because of a CR. Among the 15 patients that had a response to ruxolitinib, steroids were discontinued in 10 (67%). In the others 5 patients, a reduction >50% on the dose of the steroids was possible. Six months after stopping ruxolitinib therapy and immunosuppression, 1 patient presented with severe liver GVHD, which was successfully treated with the reintroduction of ruxolitinib in addition to steroid and mycophenolate mofetil.
All four patients who had unchanged disease to ruxolitinib had severe cGVHD-three of them had pulmonary involvement with significant sequelae and pleuroparenchymal fibroelastosis, and the other one had liver and intestinal involvement. The median number of previous therapies in this group of patients was five. Additionally, in these non-responding patients, ruxolitinib was started in very adverse conditions such as after several toxic immunosuppressive therapies and in combination with multiple concomitant infectious and clinical complications. All the non-responder patients received the drug for at least 3 months. One patient, who also was categorized as lack of response, but mixed response, had a PR in skin and mouth, but developed pulmonary cGVHD during ruxolitinib use.
Although cytopenias represent a commonly cited side effect of ruxolitinib, we only had two cases of hematological toxicity: one patient had grade 4 neutropenia and thrombocytopenia (during a refractory cytomegalovirus (CMV) infection prior to the onset of ruxolitinib), and one patient had grade 3 neutropenia. In both cases, cytopenias resolved after the ruxolitinib dose was reduced. The median follow-up time was 12 (range, 4-19) months. There were no cases of disease relapse during ruxolitinib therapy. Fifteen patients (75%) were alive at the time of this report. Overall survival was 67% at 11 months. Two patients died from severe pulmonary chronic GVHD, and three from infectious complications: one from ventilation-associated pneumonia after a pneumocystis pneumonia infection; and two from several infectious complications associated with active cGVHD that were preexisting to the onset of ruxolitinib, including the patient with refractory CMV described above. Although infections predate the onset of the drug, we cannot rule out that ruxolitinib may have contributed to the persistence of the infection and the clinical deterioration of these three patients.
An incomplete understanding of cGVHD pathophysiology and a lack of robust data limited the effective prevention and treatment of this complication for many years. Recently, a better understanding of its biology and the pathways involved in the development of GVHD has contributed to new therapeutic approaches and novel targets for treatment [3, 12] . Ruxolitinib, through JAK1/2 inhibition, appears to inhibit multiple levels of the immune response involved in cGVHD such as the proliferation of allogeneic T cells and the production of inflammatory cytokines. Additionally, it might promote T-reg cell development, leading to long-lasting tolerance. Previous studies reported that ruxolitinib reduces GVHD in mouse models, and these findings are yet to be confirmed in humans [9] .
Our results were similar to those previously reported in 2015 by Zeiser et al. [5] , the largest published experience with ruxolitinib in steroid-refractory cGVHD so far. They used ruxolitinib in 41 cGVHD patients, with an overall response rate of 85.4%, also with an excellent tolerability profile. The updated long-term follow-up results of their series was recently presented [6] . After a median follow-up of 24 months, the 1-year overall survival was 92.7%, with an estimated median overall survival not reached. GVHD relapse or progression after achieving PR/ CR was observed in 36% of the patients, and 24% of patients have an ongoing response and are free from immunosuppression. Response to retreatment with ruxolitinib or any immunosuppressive therapy was observed in 86% of cases.
Although only 7.3% of patients achieved complete remission in their series, and only three patients in ours, a PR might be sufficient for most patients, since QOL seems to be significantly improved, and many adverse events are eliminated by the withdrawal of steroids and other immunosuppressive drugs (although QOL was not formally evaluated). Limitations of our study include the small number of patients, the retrospective design of our series, and the lack of well-defined protocols to introduce ruxolitinib, as soon as we observed the failure of steroids to control active GVHD.
Hurabielle et al. [7] recently reported the use of ruxolitinib in 12 patients with severe sclerodermatous cGVHD. The drug led to a partial improvement in skin softness in the majority of the cases (8/12; 75%). Khoury et al. [8] also showed that ruxolitinib may have a role in steroiddependent cGVHD: 12/16 patients treated with ruxolitinib could reduce or discontinue steroids.
The previous article by Zeiser et al. [5] had only a few cases of disease relapse (2.4%) during ruxolitinib treatment, and there were none in our series until the time of this report, suggesting that the immunosuppressive effects of ruxolitinib do not occur at the expense of a lesser graftversus-leukemia effect. Larger patient groups and longer follow-ups, however, are needed to confirm this result.
Ruxolitinib seems to be a very good option for outpatients with cGVHD, particularly in cases with skin, mouth, and eye involvement. It seems that it should be introduced early in the course of the disease, as a secondline therapy after steroid failure, or to allow for steroid tapering. Since cGVHD usually requires therapy for many months and often years, an oral drug with minimal adverse events, such as ruxolitinib, appears to be an excellent option. However, costs remain a major concern, especially in developing countries and in public health systems. Clinical trials comparing ruxolitinib and other second-line therapies are needed to confirm these results and to possibly define ruxolitinib as one of the most efficacious and less toxic therapy for steroid-refractory cGVHD.
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